文献速递糖尿病肥胖与代谢综合征

全球糖尿病与高体重指数归因癌症负担:比较风险评估

Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-01-01

该研究估计2012年175个国家12种癌症中归因于糖尿病和高体重指数(BMI≥25 kg/m²)的癌症发病数与人群归因分值。结果显示,两者作为独立危险因素合计归因于5.7%的新发癌症(804100例),高BMI(544300例)归因癌症数约为糖尿病(293300例)的近两倍。作者认为相当数量癌症可归因于这两个因素,应关注预防和筛查措施。

要点

  • 2012年全球5.7%新发癌症归因于糖尿病和高BMI合计(804100例)。
  • 高BMI归因癌症544300例,约为糖尿病293300例的近两倍。
  • 肝癌187600例(24.5%)和子宫内膜癌121700例(38.4%)归因于这两个因素。

核心结论

  • 相当数量的癌症病例可归因于糖尿病和高体重指数。
  • 随着这些癌症危险因素患病率增加,临床和公共卫生工作应侧重于为全人群和个体患者确定最佳的预防和筛查措施。

研究设计与样本

  • 比较风险评估研究,估计2012年175个国家12种癌症按年龄和性别的归因分值。
  • 高BMI定义为BMI≥25 kg/m²,采用2002年糖尿病和BMI类别患病率估计,假设暴露与癌症发病间隔10年。
  • 结合已发表的相对危险度,分别和联合评估糖尿病与高BMI作为独立危险因素的贡献,并设保守情景假设两者风险完全重叠。
  • 使用GLOBOCAN癌症发病数据估计归因癌症例数,并估计2012年归因于1980至2002年糖尿病和高BMI患病率增加的癌症例数。
  • 所有分析在单个国家水平进行,按地区分组报告。

主要发现

  • 2012年全部新发癌症的5.7%归因于糖尿病和高BMI作为独立危险因素的联合效应,对应804100例新发病例。
  • 肝癌766000例中187600例(24.5%)和子宫内膜癌317000例中121700例(38.4%)归因于这两个危险因素。
  • 保守情景下,约4.5%(629000例新发病例)的所评估全部新发癌症归因于糖尿病和高BMI联合。
  • 单独高BMI归因544300例癌症,糖尿病归因293300例,高BMI归因癌症数约为糖尿病的近两倍。
  • 糖尿病相关癌症的25.8%(相当于75600例新发病例)和高BMI相关癌症的31.9%(174040例新发病例)归因于1980至2002年这些危险因素患病率的增加。

临床怎么用

  • 原文结论指出,随着糖尿病和高BMI患病率增加,临床和公共卫生工作应侧重于为全人群和个体患者确定最佳的预防和筛查措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes and high body-mass index (BMI) are associated with increased risk of several cancers, and are increasing in prevalence in most countries. We estimated the cancer incidence attributable to diabetes and high BMI as individual risk factors and in combination, by country and sex. METHODS: We estimated population attributable fractions for 12 cancers by age and sex for 175 countries in 2012. We defined high BMI as a BMI greater than or equal to 25 kg/m2. We used comprehensive prevalence estimates of diabetes and BMI categories in 2002, assuming a 10-year lag between exposure to diabetes or high BMI and incidence of cancer, combined with relative risks from published estimates, to quantify contribution of diabetes and high BMI to site-specific cancers, individually and combined as independent risk factors and in a conservative scenario in which we assumed full overlap of risk of diabetes and high BMI. We then used GLOBOCAN cancer incidence data to estimate the number of cancer cases attributable to the two risk factors. We also estimated the number of cancer cases in 2012 that were attributable to increases in the prevalence of diabetes and high BMI from 1980 to 2002. All analyses were done at individual country level and grouped by region for reporting. FINDINGS: We estimated that 5·7% of all incident cancers in 2012 were attributable to the combined effects of diabetes and high BMI as independent risk factors, corresponding to 804 100 new cases. 187 600 (24·5%) of 766 000 cases of liver cancer and 121 700 (38·4%) of 317 000 cases of endometrial cancer were attributable to these risk factors. In the conservative scenario, about 4·5% (629 000 new cases) of all incident cancers assessed were attributable to diabetes and high BMI combined. Individually, high BMI (544 300 cases) was responsible for almost twice as many cancer cases as diabetes (293 300 cases). 25·8% of diabetes-related cancers (equating to 75 600 new cases) and 31·9% of high BMI-related cancers (174 040 new cases) were attributable to increases in the prevalence of these risk factors from 1980 to 2002. INTERPRETATION: A substantial number of cancer cases are attributable to diabetes and high BMI. As the prevalence of these cancer risk factors increases, clinical and public health efforts should focus on identifying optimal preventive and screening measures for whole populations and individual patients. FUNDING: NIHR and Wellcome Trust.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pearson-Stuttard J, Zhou B, Kontis V, et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018. PMID: 29803268. doi:10.1016/S2213-8587(18)30150-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。